Literature DB >> 20206180

One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.

Hans F A Vasen1, Mohamed Abdirahman, Richard Brohet, Alexandra M J Langers, Jan H Kleibeuker, Mariette van Kouwen, Jan Jacob Koornstra, Henk Boot, Annemieke Cats, Evelien Dekker, Silvia Sanduleanu, Jan-Werner Poley, James C H Hardwick, Wouter H de Vos Tot Nederveen Cappel, Andrea E van der Meulen-de Jong, T Gie Tan, Maarten A J M Jacobs, Faig Lall A Mohamed, Sijbrand Y de Boer, Paul C van de Meeberg, Marie-Louise Verhulst, Jan M Salemans, Nico van Bentem, B Dik Westerveld, Juda Vecht, Fokko M Nagengast.   

Abstract

BACKGROUND & AIMS: Two percent to 4% of all cases of colorectal cancer (CRC) are associated with Lynch syndrome. Dominant clustering of CRC (non-Lynch syndrome) accounts for 1%-3% of the cases. Because carcinogenesis is accelerated in Lynch syndrome, an intensive colonoscopic surveillance program has been recommended since 1995. The aim of the study was to evaluate the effectiveness of this program.
METHODS: The study included 205 Lynch syndrome families with identified mutations in one of the mismatch repair genes (745 mutation carriers). We also analyzed data from non-Lynch syndrome families (46 families, 344 relatives). Patients were observed from January 1, 1995, until January 1, 2009. End points of the study were CRC or date of the last colonoscopy.
RESULTS: After a mean follow-up of 7.2 years, 33 patients developed CRC under surveillance. The cumulative risk of CRC was 6% after the 10-year follow-up period. The risk of CRC was higher in carriers older than 40 years and in carriers of MLH1 and MSH2 mutations. After a mean follow-up of 7.0 years, 6 cases of CRC were detected among non-Lynch syndrome families. The risk of CRC was significantly higher among families with Lynch syndrome, compared with those without.
CONCLUSIONS: With surveillance intervals of 1-2 years, members of families with Lynch syndrome have a lower risk of developing CRC than with surveillance intervals of 2-3 years. Because of the low risk of CRC in non-Lynch syndrome families, a less intensive surveillance protocol can be recommended. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206180     DOI: 10.1053/j.gastro.2010.02.053

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  81 in total

1.  Familial colorectal cancer type X syndrome: two distinct molecular entities?

Authors:  Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

2.  Controversies in the surgery of patients with familial adenomatous polyposis and Lynch syndrome.

Authors:  James M Church
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

3.  Balancing life with an increased risk of cancer: lived experiences in healthy individuals with Lynch syndrome.

Authors:  Helle Vendel Petersen; Mef Nilbert; Inge Bernstein; Christina Carlsson
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

Review 4.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

5.  Lynch Syndrome in high risk Ashkenazi Jews in Israel.

Authors:  Yael Goldberg; Inbal Kedar; Revital Kariiv; Naama Halpern; Morasha Plesser; Ayala Hubert; Luna Kaduri; Michal Sagi; Israela Lerer; Dvorah Abeliovich; Tamar Hamburger; Aviram Nissan; Hanoch Goldshmidt; Irit Solar; Ravit Geva; Hana Strul; Guy Rosner; Hagit Baris; Zohar Levi; Tamar Peretz
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

Review 6.  Familial colorectal cancer, beyond Lynch syndrome.

Authors:  Elena M Stoffel; Fay Kastrinos
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-17       Impact factor: 11.382

7.  Worldwide Practice Patterns in Lynch Syndrome Diagnosis and Management, Based on Data From the International Mismatch Repair Consortium.

Authors:  Jennifer Y Pan; Robert W Haile; Allyson Templeton; Finlay Macrae; FeiFei Qin; Vandana Sundaram; Uri Ladabaum
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-24       Impact factor: 11.382

Review 8.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

Review 9.  Role of new endoscopic techniques in Lynch syndrome.

Authors:  Jasmijn F Haanstra; Jan H Kleibeuker; Jan J Koornstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 10.  Lynch syndrome: the patients' perspective.

Authors:  Jurgen Seppen; Linda Bruzzone
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.